Historique
Rapport
WHO expert committee on drug dependence. 39th report
Auteur(s) :
OMS / WHO (Organisation mondiale de la santé / World Health Organization)
Année
2018
Page(s) :
60 p.
Langue(s) :
Anglais
Éditeur(s) :
Genève : OMS / WHO
Collection :
Rapports techniques / Technical report series, 1009
Refs biblio. :
12
Domaine :
Autres substances / Other substances ; Drogues illicites / Illicit drugs
Discipline :
PRO (Produits, mode d'action, méthode de dépistage / Substances, action mode, screening methods)
Thésaurus géographique
INTERNATIONAL
Thésaurus mots-clés
RECOMMANDATION
;
CONTROLE DES STUPEFIANTS
;
DROIT INTERNATIONAL
;
DROGUES DE SYNTHESE
;
FENTANYL
;
TRAITE INTERNATIONAL
;
CANNABINOIDES
;
PHARMACOVIGILANCE
;
POTENTIEL ADDICTIF
;
EVALUATION
;
CLASSIFICATION
Note de contenu :
CONTENTS:
1. Briefings from international organizations on their work on the public health element of the world drug problem.
2. Update from the second Informal Working Group of the ECDD.
3. Follow-up on recommendations made by the ECDD at its thirty-eighth meeting:
3.1 U-47700
3.2 Butyrfentanyl
3.3 4-MEC
3.4 Ethylone
3.5 Pentedrone
3.6 Ethylphenidate
3.7 Methiopropamine (MPA)
3.8 MDMB-CHMICA
3.9 5F-APINACA
3.10 XLR-11
4. Proposed WHO surveillance system for new psychoactive substances (NPS).
5. Review of psychoactive substances:
5.1 AB-CHMINACA
5.2 5F-ADB/5F-MDMB-PINACA
5.3 4-Fluoroamphetamine (4-FA)
5.4 AB-PINACA
5.5 Ocfentanil
5.6 Furanyl fentanyl
5.7 Acryloylfentanyl (Acrylfentanyl)
5.8 Carfentanil
5.9 4-Fluoroisobutyrfentanyl (4-FIBF, pFIBF)
5.10 Tetrahydrofuranyl fentanyl (THF-F)
5.11 UR-144
5.12 5F-PB-22
5.13 Etizolam (INN)
5.14 Pregabalin
5.15 Cannabidiol (CBD)
5.16 Tramadol
6. Cannabis pre-reviews: update on progress of planned reviews for 2018.
7. Other priorities for the ECDD.
1. Briefings from international organizations on their work on the public health element of the world drug problem.
2. Update from the second Informal Working Group of the ECDD.
3. Follow-up on recommendations made by the ECDD at its thirty-eighth meeting:
3.1 U-47700
3.2 Butyrfentanyl
3.3 4-MEC
3.4 Ethylone
3.5 Pentedrone
3.6 Ethylphenidate
3.7 Methiopropamine (MPA)
3.8 MDMB-CHMICA
3.9 5F-APINACA
3.10 XLR-11
4. Proposed WHO surveillance system for new psychoactive substances (NPS).
5. Review of psychoactive substances:
5.1 AB-CHMINACA
5.2 5F-ADB/5F-MDMB-PINACA
5.3 4-Fluoroamphetamine (4-FA)
5.4 AB-PINACA
5.5 Ocfentanil
5.6 Furanyl fentanyl
5.7 Acryloylfentanyl (Acrylfentanyl)
5.8 Carfentanil
5.9 4-Fluoroisobutyrfentanyl (4-FIBF, pFIBF)
5.10 Tetrahydrofuranyl fentanyl (THF-F)
5.11 UR-144
5.12 5F-PB-22
5.13 Etizolam (INN)
5.14 Pregabalin
5.15 Cannabidiol (CBD)
5.16 Tramadol
6. Cannabis pre-reviews: update on progress of planned reviews for 2018.
7. Other priorities for the ECDD.
Résumé :
This report presents the recommendations of the thirty-ninth WHO Expert Committee on Drug Dependence (ECDD). The ECDD is responsible for the assessment of psychoactive substances for possible scheduling under the international drug control conventions. The ECDD reviews the therapeutic usefulness, the liability for abuse and dependence, and the public health and social harm of each substance. The ECDD will advise the Director-General of WHO, to schedule or to amend the scheduling status of a substance. The Director General will, as appropriate, communicate the recommendations to the Secretary-General of the United Nations, who will in turn communicate the advice to the Commission on Narcotic Drugs (CND).
The report summarizes the review of 16 substances and the ECDD recommendations for the scheduling of 12 substances. The report also contains updates from international bodies concerned with controlled substances, as well as summaries of the follow-up on the recommendations made at the previous Committee meeting. Issues identified for consideration at future Expert Committee meetings are also covered.
The report summarizes the review of 16 substances and the ECDD recommendations for the scheduling of 12 substances. The report also contains updates from international bodies concerned with controlled substances, as well as summaries of the follow-up on the recommendations made at the previous Committee meeting. Issues identified for consideration at future Expert Committee meetings are also covered.